Navigation Links
YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Date:8/21/2007

., Ltd for Japan, Oncoscience AG in Europe, Kuhnil Pharmaceutical Co. in South Korea and Innogene Kalbiotech in Southeast Asia.

In the territories for which YM has licensed nimotuzumab, the drug is currently in varying stages of development in colorectal cancer, adult and pediatric glioma, non-small-cell lung cancer and pancreatic cancer and YM expects that the range of indications will continue to broaden in 2008 as the group's cooperative efforts expand.

In countries outside of YM's territories, nimotuzumab is in development by seven licensees and is already approved for treatment of cancers of the head and neck in a number of those including India, China, Cuba, Argentina and Columbia.

YM anticipates that the licensees will increasingly participate cooperatively to accelerate the rate of recruitment into trials of common interest, thereby reducing the costs of development for each participant, and shortening the time to completion of clinical trials.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not
'/>"/>

SOURCE YM BioSciences Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Mirus granted European patent for gene therapy
2. Info security group announces first Eastern European chapter
3. EMD Biosciences partners with European biotech company
4. Third Wave lands European distribution deal, reports high earnings
5. Speaker announces business members of IT Task Force
6. Doyle announces technology tax credits for Berbee
7. Doyle announces new energy, global warming policies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... , HOPKINTON, Mass., Dec. 3 /PRNewswire-FirstC... ), a leading provider of tools and services for d...troduced Living Image 4.0 software for IVIS® ...ves the more than 800 Caliper IVIS systems current...ge 4.0 features advanced spectral unmixing tools t...
(Date:12/2/2009)... , COLUMBIA, Md., Dec. 2 /PRNewswire-FirstCall... ) announced today that it intends to release the ... on December 16, 2009, at approximately 4:00 p.m. ... p.m. ET Martek will conduct a conference call to ...ted parties may listen to the call live via webcas...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Report...port is available in its catalogue: ,, Neurost...tp://www.reportlinker.com/p0164232/Neurostimulatio...orld neurostimulation market stands enthused by th...ant rise in age-related diseases such as, Parkinso...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Report...port is available in its catalogue: ,, Drug Di...rends & Opportunities ,, http://www.repor...-A-Global-Update-of-Market-Trends--Opportunities.h...nd ongoing element of every pharmaceutical company...
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
...an. 28 /PRNewswire-FirstCall/ - Quest PharmaTech I...t it has signed a,collaborative research agreement... a combination therapy for the treatment of lung c...mpany,s lead oncology product,SL052, with various ...photodynamic therapy (PDT) can augment the therape...
...N.J., Jan 28 Phytomedics Inc., a clinical,stage b...mponent /,multi-targeted drug products, announced ...althcare Conference in Boston, Massachusetts on We... topics of the presentation will be an overview of...ents, including Phase III development,activities r...
...x(TM) Platform Accurately Mimics a Human Capillary...national,provider of microfluidic systems in the e...y its worldwide launch of its VenaFlux(TM),Platfor...h throughput,microfluidic cell- based assay system...othelial- cell cultured microchannels, producing I...
Other Biology Technology:Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 3Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform 2
(Date:12/3/2009)...n it comes to investment in energy efficient techn...ences Research Council (EPSRC) Chief Executive Dav...and engineering research has already brought us fu...but more investment is needed to develop the capab...ur carbon emission targets by 2020 and limit the i...
(Date:12/2/2009)...results strengthen the evidence that people who sm...increased risk for developing colorectal cancer, e...This provides one more reason not to smoke, or to ...ael J. Thun, M.D., M.S., vice president emeritus, ...ican Cancer Society. "Colorectal cancer should be ...
(Date:12/2/2009)... a cancer-free status did not prompt people partic...) lung-cancer screening program to pick up their c...ished in Cancer Epidemiology, Biomarkers & Preven...ancer Research. The December issue contains a spec...gate widespread concern in the lung screening comm...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Cigarette smoking increases colorectal cancer risk 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Statins May Worsen Fatigue in Heart Failure Patients 60606 1Statins May Worsen Fatigue in Heart Failure Patients 60606 2Statins May Worsen Fatigue in Heart Failure Patients 60606 3Sun or shade 3A Pecan leaves photosynthetic light response evaluated 10611 1Sun or shade 3A Pecan leaves photosynthetic light response evaluated 10611 2A Breast Cancer Test That Saves Lives 60601 1A Breast Cancer Test That Saves Lives 60601 2A Breast Cancer Test That Saves Lives 60601 3
...ransform the dead bone of a transplanted skeletal ...g mice. The advance, which uses gene therapy to st...as living bone, is a promising development for the... who suffer with fragile and failing bone grafts. ...ppear in the March 1 issue of Nature Medicine. , ...
...ve been,viewed as the real movers and shakers in g...a messenger that shuttles information between the,...Biomedical Research,and Massachusetts Institute of...es called microRNAs regulate thousands of human ge...oding regions. In other words,a class of molecule...
...oomberg School of Public Health are exploring ways...s using genetically modified adenoviruses, a commo... vaccines have long been proven to be safe and eff...constructing a replicating live recombinant adenov...rovide longer-lasting disease protection, which wo...
Other Biology News:Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4NYU researchers simulate molecular biological clock 2Live Recombinant Adenovirus Vaccine Technique Explored 2
...ser Capture Microdissection (LCM) is the method of...ritas Microdissection is the only instrument to of...d flexibility., UV Laser Cutting provides ...n-soft tissues and capturing large numbers of cell...
Hybridizer (220 V) from Dako
...e NanoChip 400 System is an automated multiplexing... for performing SNP detection, pathogen sequence d...le samples with multiple targets can be applied to...anoChip cartridge, which may be reused until all t...
Bio-Plex Manager Version 3.0 to 4.0 Workstation Software Upgrade Kit from Bio-Rad
Biology Products: